Cobra Biologics acquires Unitech Pharma Group
11 November 2011
Cobra Biologics, an international manufacturer of
biopharmaceuticals, has acquired Unitech Pharma Group and its
bio-production facility in Matfors near Sundsvall, Sweden.
Under the terms of the agreement, Cobra Biologics will acquire
100% of the shareholding in Unitech Pharma Group, which provides a
600L clinical and commercial microbial GMP production capacity,
commercial aseptic fill/finish and lyophilisation capability.
Peter Coleman, CEO of Cobra commented: “I am delighted to
announce this acquisition as it significantly enhances Cobra’s
service offering to our customers. The facility in Matfors will
bring over 20 years of bio-production experience to Cobra, with
their offering perfectly complimenting Cobra’s existing expertise
and capacity. This is the first step as a newly independent business
in our intention to expand and grow our business, to provide the
best possible service for our customers.”
Cobra’s comprehensive service offering now includes cell line
development, analytical and process development, GMP production,
fill/finish, product release for Phase I, II, III clinical trials
and in-market supply.